VISION
Inspiring transformational change in the
field of oncology diagnostics
MISSION
To develop and deliver accurate, rapid, minimally
invasive oncology diagnostic products utilising our
patented MCM5 antibodies
Arquer Diagnostics is focused on the development and commercialisation of highly accurate minichromosome maintenance (MCM) protein based non-invasive tests for cancer diagnosis and monitoring.
Arquer aim to meet demand expressed by patients, clinicians and payers for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes.
Arquer aim to meet demand expressed by patients, clinicians and payers for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes.
Latest News
Arquer Diagnostics @Arquer Diagnostics
#BAUN had their annual conference this November in Bournemouth. Our commercial partner Alpha Diagnostics held a stand at the event to contribute, inspire and educate medical professionals about the leading research we pioneer in #oncology diagnostics. #ArquerDiagnostics #cancer https://t.co/dnsi5mNxSe
Arquer Diagnostics @Arquer Diagnostics
Arquer Diagnostics is excited to announce the results of our Bladder Recurrence Clinical Study Interim Analysis: the data are extremely consistent amongst the patient groups increasing our confidence that this product will become an important tool in fight against Bladder cancer. https://t.co/LSoahBHQUq
Arquer Diagnostics @Arquer Diagnostics
The 112th French Congress of Urology is on 21-24th Nov, where the world-leading committee will share the evolution of urology practices and technologies treating bladder, testicular and prostate cancer. The event will spark new research for better patient treatments.
#ArquerDx https://t.co/MgHcaxHNBH
Arquer Diagnostics @Arquer Diagnostics
If you're growing a moustache for Movember, don't forget to spread awareness and raise money for men's health. Prostate and testicular cancer can be treated if diagnosed early. Find out more, here: https://t.co/fI2j0CVgC1
#Arquer #ArquerDiagnostics #medical #diagnostics https://t.co/fo5fylnll0
Arquer Diagnostics @Arquer Diagnostics
"Arquer CEO Nadia Whittley Named Among Top 50 Female "Movers & Shakers" in BioBusiness Report" - the 5th annual report, compiled by BioBeat, identifies women who are developing revolutionary bioscience products for healthcare @BioBeatUK - https://t.co/fLuLfATfTy https://t.co/dMNLSbBRCv
